3 Results for "

TopBP1 BRCT7/8 domain

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "TopBP1 BRCT7/8 domain" in MCE Product Catalog:

Cat. No.: HY-189209
CAS No.: 850824-74-7
Target:  

Topoisomerase

Research Areas:  

Cancer

TopBP1-IN-3 is an inhibitor of the TopBP1 BRCT7/8 domain. TopBP1-IN-3 disrupts the BRCT7/8-dependent interactions between TopBP1 and E2F1, mutp53, MIZ1, PLK1, and CIP2A, without affecting its protein binding mediated by other BRCT domains. TopBP1-IN-3 can be used for the research of ovarian cancer and breast cancer .
loading...
    loading...
Cat. No.: HY-189208
CAS No.: 902332-77-8
Target:  

Topoisomerase Apoptosis

Research Areas:  

Cancer

TopBP1-IN-2 is an inhibitor of the TopBP1 BRCT7/8 domain, with a pS1159 phosphopeptide competition IC50 of 6 nM. TopBP1-IN-2 also blocks the direct interaction between TopBP1-BRCT7/8 and the DNA-binding domain of mutp53R273H, exhibiting an IC50 of 25 nM. TopBP1-IN-2 selectively induces cancer cell apoptosis and inhibits their clonogenic formation, with no significant effects on normal cells. TopBP1-IN-2 is applicable in research related to breast cancer and ovarian cancer .
loading...
    loading...
Cat. No.: HY-189210A
Research Areas:  

Cancer

TopBP1-IN-4 is a TopBP1 inhibitor, with an IC50 value of 2.47 to 3.8 nM against the TopBP1 BRCT7/8 domain. TopBP1-IN-4 selectively disrupts BRCT7/8-dependent oncogenic protein-protein interactions, does not interfere with other BRCT domain-mediated functions of TopBP1, and has no effect on DNA replication. TopBP1-IN-4 restores E2F1-mediated Apoptosis in cells. TopBP1-IN-4 induces mitotic catastrophe in cells. TopBP1-IN-4 overcomes Osimertinib (HY-15772) resistance in EGFR-mutant non-small cell lung cancer models. TopBP1-IN-4 can be used in studies related to triple-negative breast cancer, ovarian cancer, non-small cell lung cancer, and acute myeloid leukemia .
loading...
    loading...